NPI 1598824351: Open Payments
NPI 1598824351. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$326 in 16 payments from 10 companies in 2025. Trend: 2023 $686 · 2024 $450 · 2025 $326
Food & beverage: $326
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $62 |
| Tris Pharma Inc | 2 | $46 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Almatica Pharma LLC | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Corium, LLC | 1 | $13 |
Products named: VRAYLAR, CAPLYTA, Dyanavel XR, INGREZZA, LOREEV XR, COBENFY, Jornay PM, Qelbree.
